Compare stocks

DNA vs SCNI

Ginkgo Bioworks Holdings, Inc. and Scinai Immunotherapeutics Ltd. American Depositary Shares

Compare the businesses

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open DNA dashboard ↗

Scinai Immunotherapeutics Ltd. American Depositary Shares

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Open SCNI dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗